"Our Passion in Cancer Immunotherapy"

IMMUSE Therapeutics, Inc. develops innovative small-molecule based immunotherapies for advanced cancer.

Our exceptional expertise and experience in immuno-oncology(IO) and drug development empower us to discover IO
target(s) and develop novel IO therapies that can unleash the power of our own body’s
immune system to treat and potentially cure cancer.

Cancer immunotherapy including immune checkpoint inhibitor(s) is a promising
therapeutic approach for patients with cancers.

However, only a few patients currently benefit from treatments, which is mainly attributed to the dysfunction
of cytotoxic CD8+ T cells in a highly immunosuppressive  tumor microenvironment (TME) (Figures).

Thus, our priority in cancer immunotherapy is how to overcome the TME
and recover T cell function to eradicate cancer with high efficacy.

To tackle these challenges in immunotherapies, we are dedicated to developing small compound-based
next generation cancer immunotherapies targeting the TME and dysfunctional T cells
that can reinvigorate exhausted cytotoxic T cells to fight life-threatening cancers.

We are committed to paving the new way for better cancer treatments
that give hope for more cancer patients.